Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: A review

Abstract

Limited information is available on the pharmacokinetics and bioavailability of prednisone and prednisolone in patients with different disease states. This is partly due to difficulty in measuring these drugs in biological fluids at the usual dosages prescribed to patients. This article attempts to comprehensively review these studies categorized under the following four sections: (1) bioavailability—healthy volunteers, patients with respiratory disease, patients with liver disease, patients with kidney disease, pediatric patients with various diseases, effect of antacids, effect of food, effect of other drugs (aminophylline, cholestyramine); (2) pharmacokinetics—healthy volunteers, patients with respiratory disease, patients with liver disease, patients with kidney disease, pediatric patients with various diseases, effect of other drugs, enzyme induction of steroids and the effect on the kinetics of steroids and other drugs; (3) protein binding; and (4) analytical methods. The literature is reviewed through August 1979.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    M. E. Pickup. Clinical pharmacokinetics of prednisone and prednisolone.Clin. Pharmacokin. 4:111–128 (1979).

  2. 2.

    F. A. Campagna, G. Cureton, R. A. Mirigian, and E. Nelson. Inactive prednisone tablets USP XVI.J. Pharm. Sci. 52:605–606 (1963).

  3. 3.

    G. Levy, N. A. Hall, and E. Nelson. Studies on active prednisone tablets USP XVI.Am. J. Hasp. Pharm. 21:402 (1964).

  4. 4.

    T. J. Sullivan, E. Sakmar, K. S. Albert, D. C. Blair, and J. G. Wagner.In vitro andin vivo availability of commercial prednisone tablets.J. Pharm. Sci. 64:1723–1725 (1975).

  5. 5.

    E. T. Sugita and P. J. Niebergall. Prednisone, bioavailability monograph.J. Am. Pharm. Assoc. 15:529–532 (1975).

  6. 6.

    J. J. Thiessen. Prednisolone, bioavailability monograph.J. Am. Pharm. Assoc. 16:143–146 (1976).

  7. 7.

    L. W. Powell and E. Axelsen. Corticosteroids in liver disease: Studies on the biological conversion of prednisone to prednisolone and plasma protein binding.Gut 13:690–696 (1972).

  8. 8.

    J. S. Jenkins and P. A. Sampson. Conversion of cortisone to cortisol and prednisone to prednisolone.Br. Med. J. 2:205–207 (1967).

  9. 9.

    C. H. Gray, M. A. S. Green, N. J. Holness, and J. B. Lunnon. Urinary metabolic products of prednisone and prednisolone.J. Endocrinol. 14:146–154 (1956).

  10. 10.

    A. R. DiSanto and K. A. DeSante. Bioavailability and pharmacokinetics of prednisone in humans.J. Pharm. Sci. 64:109–112 (1975).

  11. 11.

    T. J. Sullivan, M. R. Hallmark, E. Sakmar, D. J. Weidler, R. H. Earhart, and J. G. Wagner. Comparative bioavailability: Eight commercial prednisone tablets.J. Pharmacokin. Biopharm. 4:157–172 (1976).

  12. 12.

    T. J. Sullivan, R. G. Stoll, E. Sakmar, D. C. Blair, and J. G. Wagner.In vitro andin vivo availability of some commercial prednisolone tablets.J. Pharmacokin. Biopharm. 2:29–41 (1974).

  13. 13.

    A. V. Tembo, M. R. Hallmark, E. Sakmar, H. G. Bachman, D. J. Weidler, and J. G. Wagner. Bioavailability of prednisolone tablets,J. Pharmacokin. Biopharm. 5:257–270 (1977).

  14. 14.

    A. W. Meikle, J. A. Weed, and F. H. Tyler. Kinetics and interconversion of prednisolone and prednisone studied with new radioimmunoassays.J. Clin. Endocrinol. Metab. 41:717–721 (1975).

  15. 15.

    J. Q. Rose, A. M. Yurchak, and W. J. Jusko. Bioavailability of two 50 mg prednisone formulations in man.Abstr. APhA Acad. Pharm. Sci. 8:138 (1978).

  16. 16.

    L. B. Petereit and A. W. Meikle. Effectiveness of prednisolone during phenytoin therapy.Clin. Pharmacol. Ther. 22:912–916 (1977).

  17. 17.

    A. Tanner, F. Bochner, J. Caffin, J. Halliday, and L. Powell. Dose-dependent prednisolone kinetics.Clin. Pharmacol. Ther. 25:571–578 (1979).

  18. 18.

    M. Uribe, S. W. Schalm, W. H. J. Summerskill, and V. L. W. Go. Oral prednisone for chronic active liver disease: Dose responses and bioavailability studies.Gut 19:1131–1135 (1978).

  19. 19.

    C. G. Wilson, R. Ssendagire, C. S. May, and J. W. Paterson. Measurement of plasma prednisolone in man.Br. J. Clin. Pharmacol. 2:321–325 (1975).

  20. 20.

    M. Davis, R. Williams, J. Chakraborty, J. English, V. Marks, G. Ideo, and S. Tempini. Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability.Br. J. Clin. Pharmacol. 5:501–505 (1978).

  21. 21.

    B. Hulme, V. H. T. James, and R. Rault. Absorption of enteric and non-enteric coated prednisolone tablets.Br. J. Clin. Pharmacol. 2:317–320 (1975).

  22. 22.

    R. G. Henderson, T. Wheatley, J. English, J. Chakraborty, and V. Marks. Variation in plasma prednisolone concentrations in renal transplant recipients given enteric-coated prednisolone.Br. Med. J. 1:1534–1536 (1979).

  23. 23.

    J. Gambertoglio, W. Amend, F. Vincenti, N. Feduska, J. Birnbaum, and O. Salvatierra. The pharmacokinetics of prednisone in cushingoid and noncushingoid kidney transplant patients.Clin. Res. 27:231A (1979).

  24. 24.

    G. Downes, J. Birnbaum, P. Lizak, F. Vincenti, N. Feduska, O. Salvatierra, and W. Amend. Separation from plasma extracts sephadex LH-20 of prednisone, cortisol and prednisolone: A rapid system. Submitted for publication.

  25. 25.

    O. C. Green, R. J. Winter, F. S. Kawahara, L. S. Phillips, P. R. Lewy, R. L. Hart, and L. M. Pachman. Pharmacokinetic studies of prednisolone in children.J. Pediatr. 93:299–303 (1978).

  26. 26.

    D. D. Brown and R. P. Juhl. Decreased bioavailability of digoxin due to antacids and kaolin-pectin.New Engl. J. Med. 295:1034–1037 (1976).

  27. 27.

    T. Chulski and A. A. Forist. The effects of some solid buffering agents in aqueous suspension on prednisolone.J. Am. Pharm. Assoc. Sci. Ed. 47:553–555 (1958).

  28. 28.

    A. J. Ware and B. Combes. Influence of sodium taurocholate, cholestyramine, and mylanta on the intestinal absorption of glucocorticoids in the rat.Gastroenterology 64:1150–1155 (1973).

  29. 29.

    R. L. Galeazzi, N. Gerber, and H. W. Iff. Der Einfluss von Aluminium-und Magnesiumhydroxyd (Alucol) auf die Resorption von Kortison.Schweiz. Mes. Wschr. 103:1021–1023 (1973).

  30. 30.

    A. R. Tanner, J. A. Caffln, J. W. Halliday, and L. W. Powell. Concurrent administration of antacids and prednisone: Effect on serum levels of prednisolone.Br. J. Clin. Pharmacol. 7:397–400 (1979).

  31. 31.

    A. V. Tembo, E. Sakmar, M. R. Hallmark, D. J. Weidler, and J. G. Wagner. Effect of food on the bioavailability of prednisone.J. Clin. Pharmacol. 16:620–624 (1976).

  32. 32.

    M. Uribe, S. W. Schalm, W. H. J. Summerskill, and V. L. W. Go. Effect of liquid diet on serum protein binding and prednisolone concentrations after oral prednisone.Gastroen -terology 71:362–364 (1976).

  33. 33.

    J. W. Ayres, M. Freundlich, S. Makker, J. Easton, M. Hallmark, T. Sudds, J. J. Mackichan, and J. G. Wagner. A clinically significant adverse drug interaction: Prednisone and aminophylline.APhA Acad. Pharm. Sci. Abstr. 8:133 (1978).

  34. 34.

    V. Audétat and J. Bircher. Bioavailability of prednisolone during simultaneous treatment with cholestyramine.Gastroenterology 71:1110–1111 (1976).

  35. 35.

    A. A. Sandberg and W. R. Slaunwhite. Differences in metabolism of prednisolone-C14 and cortisol-C14.J. Clin. Endocrinol. 17:1040–1050 (1957).

  36. 36.

    A. Vermeulen. The metabolism of 4-14C prednisolone.J. Endocrinol. 18:278–291 (1959).

  37. 37.

    T. Uete and N. Shimano. A simple method for separate determination of delta4- and delta1,4-corticosteroids in urine.Clin. Chem. 17:161–165 (1971).

  38. 38.

    J. English, J. Chakraborty, V. Marks, D. J. Trigger, and A. G. Thomson. Prednisolone levels in the plasma and urine: A study of two preparations in man.Br. J. Clin. Pharmacol. 2:327–332 (1975).

  39. 39.

    R. Leclercq and G. Copinschi. Patterns of plasma levels of prednisolone after oral administration in man.J. Pharmacokin. Biopharm. 2:175–187 (1974).

  40. 40.

    P. J. Morrison, I. D. Bradbrook, and H. J. Rogers. Plasma prednisolone levels from enteric and non-enteric coated tablets estimated by an original technique.Br. J. Clin. Pharmacol. 4:597–603 (1977).

  41. 41.

    R. S. Ely, A. K. Done, and V. C. Kelley. Δ1-hydrocortisone: Plasma 17-hydroxycorticosteroid concentrations following oral and I.V. administration.Proc. Soc. Exp. Biol. Med. 91:503–506 (1956).

  42. 42.

    C. A. Nugent, K. Eik-Nes, and F. H. Tyler. A comparative study of the metabolism of hydrocortisone and prednisolone.J. Clin. Endocrinol. 19:526–534 (1959).

  43. 43.

    Y. Araki, O. Yokota, T. Kato, M. Kashima, and T. Miyazaki. Dynamics of synthetic corticosteroids in man. In G. Pincus, T. Nakao, and J. F. Tait (eds.),Steroid Dynamics, Academic Press, New York, 1966, pp. 463–480.

  44. 44.

    M. Kozower, L. Veatch, and M. M. Kaplan. Decreased clearance of prednisolone, a factor in the development of corticosteroid side effects.J. Clin. Endocrinol. Metab. 38:407–412 (1974).

  45. 45.

    M. E. Pickup, J. R. Lowe, P. A. Leatham, V. M. Rhind, V. Wright, and W. W. Downie. Dose dependent pharmacokinetics of prednisolone.Eur. J. Clin. Phamacol. 12:213–219 (1977).

  46. 46.

    J. C. K. Loo, I. J. McGilveray, N. Jordan, J. Moffat, and R. Brien. Dose-dependent pharmacokinetics of prednisone and prednisolone in man.J. Pharm. Pharmacol. 30:736 (1978).

  47. 47.

    J. Q. Rose, A. M. Yurchak, and W. J. Jusko. Dose-dependent pharmacokinetics of prednisolone in man. InSeventh International Congress of Pharmacology, Abstracts, Paris, 1978, p. 400.

  48. 48.

    G. P. Lewis, W. J. Jusko, C. W. Burke, and L. Graves. Prednisone side-effects and serum-protein levels.Lancet 2:778–781 (1971).

  49. 49.

    S. W. Schalm, W. H. J. Summerskill, and V. L. W. Go. Prednisone for chronic active liver disease: Pharmacokinetics, including conversion to prednisolone.Gastroenterology 72:910–913 (1977).

  50. 50.

    P. duSouich, A. J. McLean, D. Lalka, S. Erill, and M. Gibaldi. Pulmonary disease and drug kinetics.Clin. Pharmacokin. 3:257–266 (1978).

  51. 51.

    J. Dwyer, L. Lazarus, and J. B. Hickie. A study of cortisol metabolism in patients with chronic asthma.Aust. Ann. Med. 16:297–304 (1967).

  52. 52.

    J. V. Collins, P. W. R. Harris, T. J. H. Clark, and J. Townsend. Intravenous corticosteroids in treatment of acute bronchial asthma.Lancet 2:1047–1049 (1970).

  53. 53.

    N. P. Boye, O. Djøseland, and H. N. Haugen. Protein-binding and metabolic clearance of cortisol in asthmatic patients.Scand. J. Resp. Dis. 55:200–206 (1974).

  54. 54.

    M. Uribe and V. L. W. Go. Corticosteroid pharmacokinetics in liver disease.Clin. Pharmacokin. 4:233–240 (1979).

  55. 55.

    M. Uribe, V. L. W. Go, and W. H. J. Summerskill. Kinetics and interconversion of prednisone and prednisolone compared in chronic active liver disease (CALD) after oral doses,Gastroenterologe 71:932 (1976).

  56. 56.

    A. J. Coburg, S. H. Gray, F. H. Katz, I. Penn, C. Halgrimson, and T. E. Starzl. Disappearance rates and immunosuppression of intermittent intravenously administered prednisolone in rabbits and human beings.Surg. Gyneol. Obstet. 131:933–942 (1970).

  57. 57.

    H. S. Park, J. A. Greene, and G. E. Bacon. Disappearance of high dose prednisolone from plasma after renal transplantation.Clin. Nephrol. 2:18–23 (1974).

  58. 58.

    J. G. Turcotte, N. J. Feduska, E. W. Carpenter, F. D. McDonald, and G. E. Bacon. Rejection crises in human renal transplant recipients.Arch. Surg. 105:230–236 (1972).

  59. 59.

    R. A. Sells, L. Brookes, P. Basu, and D. Whitemore. Methylprednisolone blood levels in cadaveric renal allograft recipients.Transplant. Proc. 10:651–653 (1978).

  60. 60.

    M. Uribe, W. H. J. Summerskill, and V. L. W. Go. Why hyperbilirubinemia and hypoalbuminemia predispose to steroid side effects during treatment of chronic active liver disease (CALD).Gastroenterology 72:1143 (1977).

  61. 61.

    E. Englert, H. Brown, D. G. Willardson, S. Wallach, and E. L. Simons. Metabolism of free and conjugated 17-hydroxycorticosteroids in subjects with uremia.J. Clin. Endocrinol. 18:36–48 (1958).

  62. 62.

    L. Raith, H. J. Gurland, and H. J. Karl. Abbau und Ausscheidung von 4-14C-Cortisol nach beidseitiger Nephrektomie.Verh. Deutsch. Ges. Inn. Med. 73:1110–1114 (1967).

  63. 63.

    M. S. Mishkin, T-H. Hsu, W. G. Walker, and T. Bledsoe. Studies on the episodic secretion of cortisol in uremic patients on hemodialysis.Johns Hopkins Med. J. 131:160–164 (1972).

  64. 64.

    P. Kramer, D. Matthaei, R. Arnold, R. Ebert, D. Köbberling, C. McIntosh, E. Schwinn, F. Scheler, H. Ludwig, J. Reichel, and G. Spitella. Changes of plasma concentration and elimination of various hormones by haemofiltration.Dial. Trans. Nephrol. 14:144–150 (1977).

  65. 65.

    P. Boer and J. H. H. Thijssen. The excretion of metabolites of cortisol and aldosterone in male patients on haemodialysis treatment.Steroids 30:203–211 (1977).

  66. 66.

    J. E. Sherlock and J. M. Letteri. Effect of hemodialysis on methylprednisolone plasma levels.Nephron 18:208–211 (1977).

  67. 67.

    S. J. Wassner, A. J. Pennisi, M. H. Malekzadeh, and R. N. Fine. The adverse effect of anticonvulsant therapy on renal allograft survival.J. Pediatr. 88:134–137 (1976).

  68. 68.

    S. J. Wassner, M. H. Malekzadeh, A. J. Pennisi, R. B. Ettenger, C. H. Uittenbogaart, and R. N. Fine. Allograft survival in patients receiving anticonvulsant medications.Clin. Nephrol. 8:293–297 (1977).

  69. 69.

    P. T. McEnery and D. A. Stempel. Commentary: Anticonvulsant therapy and renal allograft survival.J. Pediatr. 88:138–139 (1976).

  70. 70.

    Y. Choi, K. Thrasher, E. E. Werk, L. J. Sholiton, and C. Olinger. Effect of diphenylhydantoin on cortisol kinetics in humans.J. Pharmacol. Exp. Ther. 176:27–34 (1971).

  71. 71.

    E. E. Werk, J. MacGee, and L. J. Sholiton. Effect of diphenylhydantoin on cortisol metabolism in man.J. Clin. Invest. 43:1824–1835 (1964).

  72. 72.

    W. Jubiz, A. W. Meikle, R. A. Levinson, S. Mizutani, C. D. West, and F. H. Tyler. Effect of diphenylhydantoin on the metabolism of dexamethasone.New Engl. J. Med. 283:11–14 (1970).

  73. 73.

    N. Haque, K. Thrasher, E. E. Werk, H. C. Knowles, and L. J. Sholiton. Studies on dexamethasone metabolism in man: Effect of diphenylhydantoin.J. Clin. Endocrinol. Metab. 34:44–50 (1972).

  74. 74.

    S. M. Brooks, E. E. Werk, S. J. Ackerman, I. Sullivan, and K. Thrasher. Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma.New Engl. J. Med. 286:1125–1128 (1972).

  75. 75.

    M. R. Stjernholm and F. H. Katz. Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate.J. Clin. Endocrinol. Metab. 41:887–893 (1975).

  76. 76.

    P. M. Brooks, W. W. Buchanan, M. Grove, and W. W. Downie. Effects of enzyme induction on metabolism of prednisolone.Ann. Rheum. Dis. 35:339–343 (1976).

  77. 77.

    G. A. Buffington, J. H. Dominguez, W. F. Piering, L. A. Hebert, H. M. Kauffman, and J. Lemann. Interaction of rifampin and glucocorticoids: Adverse effect on renal allograft function.J. Am. Med. Assoc. 236:1958–1960 (1976).

  78. 78.

    O. M. Edwards, R. J. Courtenay-Evans, J. M. Galley, J. Hunter, and A. D. Tait. Changes in cortisol metabolism following rifampicin therapy.Lancet 2:549–551 (1974).

  79. 79.

    W. Hendrickse, J. McKiernan, M. Pickup, and J. Lowe. Rifampicin-induced nonresponsiveness to corticosteroid treatment in nephrotic syndrome.Br. Med. J. 1:306 (1979).

  80. 80.

    W. Van Marle, K. L. Woods, and L. Beeley. Concurrent steroid and rifampicin therapy.Lancet 1:1020 (1979).

  81. 81.

    J. R. Klinenberg and F. Miller. Effect of corticosteroids on blood salicylate concentration.J. Am. Med. Assoc. 194:131–134 (1965).

  82. 82.

    G. Graham, G. D. Champion, R. O. Day, and P. D. Paull. Pharmacokinetics of salicylate in subjects with rheumatoid arthritis.Aust. N.Z. J. Med. 5:500 (1975).

  83. 83.

    G. G. Graham, G. D. Champion, R. O. Day, and P. D. Paull. Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis.Clin. Pharmacol. Ther. 22:410–420 (1977).

  84. 84.

    M. Bardare, G. U. Cislaghi, M. Mandelli, and F. Sereni. Value of monitoring plasma salicylate levels in treating juvenile rheumatoid arthritis.Arch. Dis. Child. 53:381–385 (1978).

  85. 85.

    P. Kourounakis and H. Selye. Actions of prednisolone acetate, pregnenolone-16αcarbonitrite, and triamcinolone upon drug resistance and metabolism: A comparative study.Can. J. Physiol. Pharmacol. 55:363–366 (1977).

  86. 86.

    T. Hayakawa, N. Kanai, R. Yamada, R. Kuroda, H. Higashi, H. Mogami, and D. Jinnai. Effect of steroid hormone on activation of endoxan (cyclophosphamide).Biochem. Pharmacol. 18:129–135 (1969).

  87. 87.

    G. K. Hanasono and L. J. Fischer. Plasma levels and urinary excretion of [14C]cyclophosphamide and its radioactive metabolites in rats pretreated with prednisolone.Biochem. Pharmacol. 21:272–276 (1972).

  88. 88.

    W. J. Jusko and M. Gretch. Plasma and tissue protein binding of drugs in pharmacokinetics.Drug. Metab. Rev. 5:43–140 (1976).

  89. 89.

    W. J. Jusko. Pharmacokinetics in disease states changing protein binding. In L. Z. Benet (ed.),The Effect of Disease States on Drug Pharmacokinetics, American Pharmaceutical Association, Academy of Pharmaceutical Sciences, 1976, pp. 99–123.

  90. 90.

    W. R. Slaunwhite and A. A. Sandberg. The metabolism of 1-dehydro-17-hydroxycorticosteroids in human subjects.J. Clin. Endocrinol. Metab. 17:395–406 (1957).

  91. 91.

    P. S. Chen, I. H. Mills, and F. C. Bartter. Ultrafiltration studies of steroid-protein binding.J. Endocrinol. 23:129–137 (1961).

  92. 92.

    F. Centeno, G. Robles, M. Uribe, S. G. Lozada, and G. I. Suárez. Nomogram for prednisone-prednisolone adjustment dose in patients with hypoalbuminemia.Rev. Invest. Clin. (Mex.) 32:35–39 (1978).

  93. 93.

    M. Uribe, A. M. Wolf, and W. H. J. Summerskill. Steroid side effects during therapy of chronic active liver disease (CALD): What to expect.Gastroenterology 71:932 (1976).

  94. 94.

    A. Angeli, R. Frajria, R. De Paoli, D. Fonzo, and F. Ceresa. Diurnal variation of prednisolone binding to serum corticosteroid-binding globulin in man.Clin. Pharmacol. Ther. 23:47–53 (1978).

  95. 95.

    G. E. Bacon and S. Kokenakes. Measurement of plasma prednisolone by gas chromatography.J. Lab. Clin. Med. 73:1030–1035 (1969).

  96. 96.

    P. F. D'Arcy, J. P. Griffin, J. S. Jenkins, W. F. Kirk, and A. W. C. Peacock. Sustainedrelease formulation of prednisolone administered orally to man.J. Pharm. Sci. 60:1028–1033 (1971).

  97. 97.

    B. E. P. Murphy. Some studies of the protein-binding of steroids and their application to the routine micro and ultramicro measurement of various steroids in body fluids by competitive protein-binding radioassay.J. Clin. Endocrinol. 27:973–990 (1967).

  98. 98.

    J. English, J. Chakraborty, and V. Marks. A competitive protein binding method for plasma prednisolone assay.Ann. Clin. Biochem. 11:11–14 (1974).

  99. 99.

    D. H. Sandberg, C. Z. Bacallao, and W. W. Cleveland. Measurement of plasma prednisolone by a competitive protein-binding assay.Biochem. Med. 4:383–390 (1970).

  100. 100.

    A. K. Turner, C. J. Carroll, J. L. Pinkus, D. Charles, and S. C. Chattaoraj. Simultaneous competitive protein binding assay for cortisol, cortisone, and prednisolone in plasma and its clinical application.Clin. Chem. 19:731–736 (1973).

  101. 101.

    W. A. Colburn and R. H. Buller. Radioimmunoassay for prednisolone.Steroids 21:833–846 (1973).

  102. 102.

    W. A. Colburn. Radioimmunoassay for prednisone.Steroids 24:95–106 (1974).

  103. 103.

    S. W. Schalm, W. H. J. Summerskill, and V. L. W. Go. Development of radioimmunoassays for prednisone and prednisolone: Application to studies of hepatic metabolism of prednisone.Mayo Clin. Proc. 51:761–766 (1976).

  104. 104.

    J. A. Caffin, J. W. Halliday, and L. W. Powell. Specific assays for prednisolone and prednisone in serum: Lipidex chromatography followed by radioimmunoassay.J. Phar. Meth. 1:223–231 (1978).

  105. 105.

    J. Chakraborty, J. English, V. Marks, M. C. Dumasia, and D. J. Chapman. A radioimmunoassay method for prednisolone: Comparison with the competitive protein binding method.Br. J. Clin. Pharmacol. 3:903–906 (1976).

  106. 106.

    A. V. Tembo, M. A. Schork, and J. G. Wagner. Statistical survey of “saturation analysis” calibration curve data for prednisolone, prednisone and digoxin.Steroids 28:387–403 (1976).

  107. 107.

    S. B. Matin and B. Amos. Quantitative determination of prednisone and prednisolone in human plasma using GLC and chemical-ionization mass spectrometry.J. Pharm. Sci. 67:923–926 (1978).

  108. 108.

    J. C. K. Loo, A. G. Butterfield, J. Moffat, and N. Jordon. Analysis of prednisolone in plasma by high-performance liquid chromatography.J. Chromatogr. 143:275–280 (1977).

  109. 109.

    J. C. K. Loo and N. Jordan. High-performance liquid chromatographie analysis for synthetic corticosteroids in plasma.J. Chromatogr. 143:314–316 (1977).

  110. 110.

    J. Q. Rose and W. J. Jusko. Corticosteroid analysis in biological fluids by highperformance liquid chromatography.J. Chromatogr. 162:273–280 (1979).

  111. 111.

    K. F. Trefz, D. J. Byrd, and W. Kochen. Quantitative determination of cortisol in human plasma by high-pressure liquid chromatography.J. Chromatogr. 107:181–189 (1975).

  112. 112.

    C. P. DeVries, C. Popp-Snijders, W. De Kieviet, and A. C. Akkerman-Faber. Use of high-pressure liquid chromatography in the assay of aldosterone in urine.J. Chromatogr. 143:624–627 (1977).

  113. 113.

    D. C. Garg, J. W. Ayres, and J. G. Wagner. Determination of methylprednisolone and hydrocortisone in plasma using high pressure liquid chromatography.Res. Commun. Chem. Pathol. Pharmacol. 18:137–146 (1977).

  114. 114.

    P. M. Kabra, L. L. Tsai, and L. J. Marton. Improved liquid Chromatographie method for determination of serum cortisol.Clin. Chem. 25:1293–1296 (1979).

  115. 115.

    G. E. Reardon, A. M. Caldarella, and E. Canalis. Determination of serum cortisol and 11-deoxycortisol by liquid chromatography.Clin. Chem. 25:122–126 (1979).

  116. 116.

    V. K. H. Müller and B. Stuber. Hochdruckflüssigkeitschromatographie von Prednisolon und Hexachlorophen.Pharm. Acta Helv. 53:124 (1978).

  117. 117.

    S. E. Tsuei, J. J. Ashley, B. G. Moore, and W. G. McBride. Quantitation of dexamethasone in biological fluids using high-performance liquid chromatography.J. Chromatogr. 145:213–220 (1978).

  118. 118.

    F. J. Frey, B. M. Frey, and L. Z. Benet. Liquid-chromatographic measurement of endogenous and exogenous glucocorticoids in plasma.Clin. Chem. 25:1944–1947 (1979).

Download references

Author information

Correspondence to John G. Gambertoglio.

Additional information

This report was supported in part by National Institutes of Health Center Grant GM26691.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gambertoglio, J.G., Amend, W.J.C. & Benet, L.Z. Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: A review. Journal of Pharmacokinetics and Biopharmaceutics 8, 1–52 (1980). https://doi.org/10.1007/BF01059447

Download citation

Key words

  • prednisone
  • prednisolone
  • glucocorticoids
  • corticosticosteroids